RNAZ (TransCode Therapeutics) Net Profit

Official company branding of transcodetherapeutics.com (RNAZ)

TransCode Therapeutics (RNAZ) net profit is independent of GDP, as the development of RNA drugs follows a medical schedule. The company's accumulated profit on the GURU.Markets service displays this chart, where -0.05 reflects the latest metric value. The business relies on nanoparticles to combat cancer in the US, however, a cash gap forces management to regularly conduct share issuances.

RNAZ - TransCode Therapeutics Company Net Income over the range 07/04/2022 - 10/30/2026

Analytical breakdowns and data insights for company transcodetherapeutics.com (RNAZ)

- stock price and consensus target price:
Price Performance Chart TransCode Therapeutics, Inc.|RNAZ - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization TransCode Therapeutics|RNAZ - Total Company Value
- book capitalization data:
Equity per Share TransCode Therapeutics|RNAZ - Company Book Value|Market Capitalization to Book Value transcodetherapeutics.com|RNAZ - Company Total Assets
- debt and liquidity details:
Total Debt to Equity Ratio TransCode Therapeutics|RNAZ - Long-Term Debt to Equity|Current Liabilities to Capital TransCode Therapeutics, Inc.|RNAZ - Company Aggregate Debts|Debt to Book Value Ratio TransCode Therapeutics|RNAZ - Company Long-Term Debts|Short-Term Debt TransCode Therapeutics|Intermediate Coverage Ratio transcodetherapeutics.com
- earnings and market ratios statistics:
RNAZ - Net Income
Fundamental valuation:TransCode
Core merchandise of TransCode Therapeutics

TransCode Therapeutics (RNAZ) focuses on developing innovative RNA therapies, yet the absence of commercial sales makes this metric of the company's financial success a reflection solely of net cash flow. This indicator aggregates daily changes in net income, allowing investors to track the burn rate and the biotech's reliance on external financing during early preclinical stages of development.

Direct competitors

Tempus AI - Final Profit|QGEN (Qiagen N.V.) - Net Profit|Net Profit ionispharma.com|Company Net Income Repligen (RGEN)|Avidity Biosciences Inc - Company Profit|Company Net Income CRISPR Therapeutics Corp CRSP|Net Financial Result GeneDx Corp (WGS)|Ultragenyx Pharmaceutical - Net Profit|beamtx.com (BEAM) - Net Income|Sarepta (SRPT) - Company Net Income|Company Net Income Twist Bioscience Inc (TWST)|TXG (10x Genomics Corp) - Net Profit|Company Profit NTLA (Intellia Corp)|Net Profit STOK|BLFS - Company Net Income|Wave Life Sciences Ltd. - Net Income|Final Profit MAZE|SION: Net Income|Prime Medicine Bio - Profit After Payment of Taxes|TSHA: Net Profit|uniqure.com - Final Profit|MGTX (MeiraGTx) - Net Profit|Company Net Income REGENXBIO Inc RGNX|Company Net Income Solid Bio (SLDB)|OCGN (Ocugen Pharma) - Final Profit|Net Profit PACB (Pacific Biosciences)|Net Profit benitec.com BNTC|DSGN - Company Net Income|Profit After Tax RCKT|FDMT: Net Profit|Company Net Income Lexeo Therapeutics, Inc. (LXEO)|Net Income KRRO|Net Profit editasmedicine.com|Net Income SLN (Silence Therapeutics plc)|Profit After Payment of Taxes PRQR|Net Profit CDXS (Codexis)|Net Financial Result Sangamo BioSciences (SGMO)|Nautilus Biotechnology Inc - Net Profit|metagenomi.co (MGX) - Net Income|Precision BioSciences (DTIL) - Company Net Income|GBIO - Net Financial Result|Company Net Income Boundless Bio, Inc|XCUR: Final Profit|Company Net Income Imunon, Inc. (IMNN)|phiopharma.com - Company Profit|Net Profit MBIO (Mustang Bio)|Net Profit Bionano Genomics Inc. BNGO|APDN: Net Income|Profit After Tax BLUE|IPA: Net Profit|Company Profit OMGA|Company Net Income Singular Genomics|Company Profit RGLS (Regulus Therapeutics, Inc.)|Net Profit SYRS|Net Profit Telesis Bio, Inc (TBIO)|TRACON Pharmaceuticals - Net Income|Profit After Payment of Taxes UBX (unitybiotechnology.com)